KRAS and neoplasm: Although the mechanisms underlying overactivation of the ERK1/2 pathway across different tumors share strong similarities, such as mutations in KRAS, BRAF, or FGFR2 fusions, it is crucial to consider the extent to which a tumor truly depends on ERK1/2 signaling to sustain its continuous growth and survival [118].